Want to see TRDA full AI Analyst Report?

Entrada Therapeutics Inc (TRDA) Price & Analysis

Q: What was Entrada Therapeutics Inc’s price range in the past 12 months?

Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $16.45 in the past 12 months.

Q: What is Entrada Therapeutics Inc’s market cap?

Entrada Therapeutics Inc’s market cap is $284.17M.

Q: When is Entrada Therapeutics Inc’s upcoming earnings report date?

Entrada Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 34 days.

Q: How were Entrada Therapeutics Inc’s earnings last quarter?

Entrada Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.037 by $0.087.

Q: Is Entrada Therapeutics Inc overvalued?

According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Entrada Therapeutics Inc pay dividends?

Entrada Therapeutics Inc does not currently pay dividends.

Q: What is Entrada Therapeutics Inc’s EPS estimate?

Entrada Therapeutics Inc’s EPS estimate is -1.05.

Q: How many shares outstanding does Entrada Therapeutics Inc have?

Entrada Therapeutics Inc has 38,820,618 shares outstanding.

Q: What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?

Entrada Therapeutics Inc reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.037. Following the earnings report the stock price went down -57.268%.

Q: Which hedge fund is a major shareholder of Entrada Therapeutics Inc?

Currently, no hedge funds are holding shares in TRDA

160 Followers

TRDA Stock Chart & Stats

$13.99

-$0.56(-3.25%)

At close: Jan 08 4:00 PM EST

$13.99

-$0.56(-3.25%)

Day’s Range― - ―

52-Week Range$4.93 - $16.45

Previous CloseN/A

Volume35.15K

Average Volume (3M)302.96K

Market Cap

$284.17M

Enterprise Value$237.67M

Total Cash (Recent Filing)$254.86M

Total Debt (Recent Filing)$49.75M

Price to Earnings (P/E)―

Beta1.18

Next Earnings

Aug 12, 2026

EPS Estimate

-1.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.00

Shares Outstanding38,820,618

10 Day Avg. Volume354,012

30 Day Avg. Volume302,958

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)1.39

Price to Sales (P/S)16.73

P/FCF Ratio-3.28

Enterprise Value/Market Cap0.84

Enterprise Value/Revenue41.42

Enterprise Value/Gross Profit-6.93

Enterprise Value/Ebitda-1.44

Forecast

1Y Price Target

$18.75

Price Target Upside34.02% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-3.91

Revenue Forecast (FY)$19.51M

Bulls Say, Bears Say

Bulls Say

Diversified Clinical PipelineEntrada's portfolio spans multiple genetic indications (DMD, DM1, inherited retinal diseases), creating several staggered clinical catalysts through 2026. This diversification reduces binary single-program risk, increases chances of at least one de-risking event, and supports longer-term developer economics and partner interest.

Positive Early Clinical DataStatistically significant functional improvement and a clean safety profile in Phase 1/2 Cohort 1 materially strengthen the therapeutic hypothesis and platform credibility. Durable clinical signals and tolerability increase the probability of progression, enable partnerships, and underpin longer-term commercial potential in DMD.

Relatively Healthy Balance Sheet MetricsDebt levels are low versus equity, and reported equity reserves provide financial flexibility. Modest leverage reduces solvency pressure and, together with disclosed cash runway, supports multi-quarter development investing without immediate refinancing, preserving operational continuity while programs advance.

Bears Say

High Cash BurnSustained negative operating and free cash flow at ~-$132M TTM drains liquidity and forces reliance on external financing or partnerships. Over months this elevates dilution risk, constrains discretionary R&D spending, and pressures timeline flexibility for longer development programs if burn isn't reduced.

Revenue Collapse And Earnings VolatilityA ~77% revenue decline and a swing to a large net loss reflect volatile non-recurring collaboration revenue and weak operating leverage. Such swings complicate forecasting, increase dependence on milestone-driven financing, and raise execution risk for sustaining long-term R&D and commercialization plans.

Dilution Risk From Equity Plan ExpansionExpanding equity compensation pools increases potential share issuance over time. Combined with high cash burn and episodic collaboration revenue, reliance on equity-based funding and compensation heightens dilution risk for existing holders and can pressure per-share economics if further capital raises are required.

Entrada Therapeutics Inc News

Entrada Therapeutics Stockholders Approve Directors and Equity Plans

Entrada Therapeutics Inc ( ($TRDA) ) has issued an announcement. Entrada Therapeutics Inc. held its Annual Meeting of...

29d ago

TRDA

Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim

Guggenheim lowered the firm’s price target on Entrada Therapeutics (TRDA) to $17 from $20 and keeps a Buy...

1M ago

TRDA

Entrada Therapeutics Highlights Transformational Year and Pipeline Progress

The latest announcement is out from Entrada Therapeutics Inc ( ($TRDA) ). On May 18, 2026, Entrada Therapeutics...

2M ago

TRDA

Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital

Roth Capital lowered the firm’s price target on Entrada Therapeutics (TRDA) to $10 from $19 and keeps a...

2M ago

NVS

TRDA

Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju downgraded Entrada Therapeutics (TRDA) to Neutral from Buy without a price target saying...

2M ago

TRDA

Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study

Entrada Therapeutics (TRDA) announced topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of...

2M ago

TRDA

Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst

TD Cowen analyst Joseph Thome has maintained their bullish stance on TRDA stock, giving a Buy rating today....

2M ago

TRDA

Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)

Reports Q1 revenue $875,000, consensus $2.92M. “With the recently announced positive data from Cohort 1 of our ELEVATE-44-201...

2M ago

TRDA

Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data

Entrada Therapeutics Inc ( ($TRDA) ) has issued an announcement. On May 7, 2026, Entrada Therapeutics reported first-quarter...

2M ago

TRDA

Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer

Oppenheimer raised the firm’s price target on Entrada Therapeutics (TRDA) to $23 from $21 and keeps an Outperform...

3M ago

TRDA

Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Entrada Therapeutics (TRDA) with an Overweight rating. Entrada is developing a cyclic cell-penetrating...

3M ago

TRDA

Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Entrada Therapeutics (TRDA) with an Overweight rating. Published first on TheFly – the...

3M ago

TRDA

Entrada Therapeutics management to meet with Oppenheimer

Meeting to be held on April 2 hosted by Oppenheimer. Published first on TheFly – the ultimate source...

3M ago

TRDA

Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics

Entrada Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju...

4M ago

TRDA

TRDA FAQ

What was Entrada Therapeutics Inc’s price range in the past 12 months?

Entrada Therapeutics Inc lowest stock price was $4.93 and its highest was $16.45 in the past 12 months.

What is Entrada Therapeutics Inc’s market cap?

Entrada Therapeutics Inc’s market cap is $284.17M.

When is Entrada Therapeutics Inc’s upcoming earnings report date?

Entrada Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 34 days.

How were Entrada Therapeutics Inc’s earnings last quarter?

Entrada Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.037 by $0.087.

Is Entrada Therapeutics Inc overvalued?

According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Entrada Therapeutics Inc pay dividends?

Entrada Therapeutics Inc does not currently pay dividends.

What is Entrada Therapeutics Inc’s EPS estimate?

Entrada Therapeutics Inc’s EPS estimate is -1.05.

How many shares outstanding does Entrada Therapeutics Inc have?

Entrada Therapeutics Inc has 38,820,618 shares outstanding.

What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?

Entrada Therapeutics Inc reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.037. Following the earnings report the stock price went down -57.268%.

Which hedge fund is a major shareholder of Entrada Therapeutics Inc?

Currently, no hedge funds are holding shares in TRDA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Entrada Therapeutics Inc Stock Smart Score

Outperform

Fundamentals

Return on Equity

-51.22%

Trailing 12-Months

Asset Growth

-31.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Entrada Therapeutics Inc

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

Entrada Therapeutics Inc (TRDA) Earnings & Revenues

Historic Earnings Reports

TRDA Stock 12 Month Forecast

Average Price Target

$18.75

▲(34.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.59,8.929230769230768,10.268461538461539,11.607692307692307,12.946923076923078,14.286153846153846,15.625384615384615,16.964615384615385,18.303846153846152,19.643076923076922,20.982307692307693,22.32153846153846,23.66076923076923,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.59,8.448461538461538,9.306923076923077,10.165384615384616,11.023846153846154,11.882307692307691,12.740769230769232,13.599230769230768,14.457692307692309,15.316153846153846,16.174615384615386,17.033076923076923,17.89153846153846,{"y":18.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.59,7.775384615384615,7.96076923076923,8.146153846153846,8.331538461538461,8.516923076923076,8.702307692307691,8.887692307692308,9.073076923076924,9.258461538461539,9.443846153846154,9.62923076923077,9.814615384615385,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.88,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.91,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >